E
Vaxil Bio Ltd.
VXLLF
$0.008
$0.00233.33%
E
Sell
3/27/2025Downgrade
Vaxil Bio Ltd. (VXLLF) was downgraded to E+ from D- on 3/27/2025 due to a decline in the volatility index.
Vaxil Bio Ltd. (VXLLF) was downgraded to E+ from D- on 3/27/2025 due to a decline in the volatility index.
D
Sell
3/10/2025Upgraded
Vaxil Bio Ltd. (VXLLF) was upgraded to D- from E+ on 3/10/2025 due to an increase in the volatility index.
Vaxil Bio Ltd. (VXLLF) was upgraded to D- from E+ on 3/10/2025 due to an increase in the volatility index.
E
Sell
2/11/2025Downgrade
Vaxil Bio Ltd. (VXLLF) was downgraded to E+ from D- on 2/11/2025 due to a decline in the volatility index.
Vaxil Bio Ltd. (VXLLF) was downgraded to E+ from D- on 2/11/2025 due to a decline in the volatility index.
D
Sell
1/27/2025Upgraded
Vaxil Bio Ltd. (VXLLF) was upgraded to D- from E+ on 1/27/2025 due to an increase in the volatility index and total return index.
Vaxil Bio Ltd. (VXLLF) was upgraded to D- from E+ on 1/27/2025 due to an increase in the volatility index and total return index.
E
Sell
3/27/2024Downgrade
Vaxil Bio Ltd. (VXLLF) was downgraded to E+ from D- on 3/27/2024 due to a noticeable decline in the volatility index and total return index.
Vaxil Bio Ltd. (VXLLF) was downgraded to E+ from D- on 3/27/2024 due to a noticeable decline in the volatility index and total return index.
D
Sell
3/8/2024Upgraded
Vaxil Bio Ltd. (VXLLF) was upgraded to D- from E+ on 3/8/2024 due to a large increase in the total return index, volatility index and growth index. Operating cash flow increased 82.43% from -$207.7 to -$36.5, EBIT increased 73.97% from -$94.5 to -$24.6, and earnings per share increased from -$0.0007 to -$0.0002.
Vaxil Bio Ltd. (VXLLF) was upgraded to D- from E+ on 3/8/2024 due to a large increase in the total return index, volatility index and growth index. Operating cash flow increased 82.43% from -$207.7 to -$36.5, EBIT increased 73.97% from -$94.5 to -$24.6, and earnings per share increased from -$0.0007 to -$0.0002.
E
Sell
3/14/2023Downgrade
Vaxil Bio Ltd. (VXLLF) was downgraded to E+ from D on 3/14/2023 due to a decline in the volatility index.
Vaxil Bio Ltd. (VXLLF) was downgraded to E+ from D on 3/14/2023 due to a decline in the volatility index.
D
Sell
2/23/2023Upgraded
Vaxil Bio Ltd. (VXLLF) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index.
Vaxil Bio Ltd. (VXLLF) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index.
D
Sell
2/8/2023Downgrade
Vaxil Bio Ltd. (VXLLF) was downgraded to D- from D on 2/8/2023 due to a decline in the total return index and valuation index.
Vaxil Bio Ltd. (VXLLF) was downgraded to D- from D on 2/8/2023 due to a decline in the total return index and valuation index.
D
Sell
12/29/2022Upgraded
Vaxil Bio Ltd. (VXLLF) was upgraded to D from D- on 12/29/2022 due to an increase in the total return index and volatility index.
Vaxil Bio Ltd. (VXLLF) was upgraded to D from D- on 12/29/2022 due to an increase in the total return index and volatility index.
D
Sell
12/12/2022Downgrade
Vaxil Bio Ltd. (VXLLF) was downgraded to D- from D on 12/12/2022 due to a decline in the volatility index and total return index.
Vaxil Bio Ltd. (VXLLF) was downgraded to D- from D on 12/12/2022 due to a decline in the volatility index and total return index.
D
Sell
11/25/2022Upgraded
Vaxil Bio Ltd. (VXLLF) was upgraded to D from D- on 11/25/2022 due to an increase in the volatility index.
Vaxil Bio Ltd. (VXLLF) was upgraded to D from D- on 11/25/2022 due to an increase in the volatility index.
D
Sell
11/4/2022Downgrade
Vaxil Bio Ltd. (VXLLF) was downgraded to D- from D on 11/4/2022 due to a decline in the volatility index.
Vaxil Bio Ltd. (VXLLF) was downgraded to D- from D on 11/4/2022 due to a decline in the volatility index.
D
Sell
10/20/2022Upgraded
Vaxil Bio Ltd. (VXLLF) was upgraded to D from D- on 10/20/2022 due to an increase in the volatility index and total return index.
Vaxil Bio Ltd. (VXLLF) was upgraded to D from D- on 10/20/2022 due to an increase in the volatility index and total return index.
D
Sell
10/4/2022Downgrade
Vaxil Bio Ltd. (VXLLF) was downgraded to D- from D on 10/4/2022 due to a decline in the volatility index and total return index.
Vaxil Bio Ltd. (VXLLF) was downgraded to D- from D on 10/4/2022 due to a decline in the volatility index and total return index.
D
Sell
9/19/2022Upgraded
Vaxil Bio Ltd. (VXLLF) was upgraded to D from D- on 9/19/2022 due to an increase in the volatility index.
Vaxil Bio Ltd. (VXLLF) was upgraded to D from D- on 9/19/2022 due to an increase in the volatility index.
D
Sell
9/2/2022Downgrade
Vaxil Bio Ltd. (VXLLF) was downgraded to D- from D on 9/2/2022 due to a decline in the volatility index.
Vaxil Bio Ltd. (VXLLF) was downgraded to D- from D on 9/2/2022 due to a decline in the volatility index.
D
Sell
8/12/2022Upgraded
Vaxil Bio Ltd. (VXLLF) was upgraded to D from D- on 8/12/2022 due to an increase in the volatility index.
Vaxil Bio Ltd. (VXLLF) was upgraded to D from D- on 8/12/2022 due to an increase in the volatility index.
D
Sell
7/28/2022Downgrade
Vaxil Bio Ltd. (VXLLF) was downgraded to D- from D on 7/28/2022 due to a noticeable decline in the total return index, volatility index and solvency index.
Vaxil Bio Ltd. (VXLLF) was downgraded to D- from D on 7/28/2022 due to a noticeable decline in the total return index, volatility index and solvency index.
D
Sell
4/29/2022Upgraded
Vaxil Bio Ltd. (VXLLF) was upgraded to D from D- on 4/29/2022 due to an increase in the growth index. Operating cash flow increased 55.5% from -$237.3 to -$105.6.
Vaxil Bio Ltd. (VXLLF) was upgraded to D from D- on 4/29/2022 due to an increase in the growth index. Operating cash flow increased 55.5% from -$237.3 to -$105.6.
D
Sell
4/20/2022Downgrade
Vaxil Bio Ltd. (VXLLF) was downgraded to D- from D on 4/20/2022 due to a large decline in the total return index, growth index and solvency index. EBIT declined 11.46% from -$170.2 to -$189.7, and earnings per share declined from -$0.0013 to -$0.0014.
Vaxil Bio Ltd. (VXLLF) was downgraded to D- from D on 4/20/2022 due to a large decline in the total return index, growth index and solvency index. EBIT declined 11.46% from -$170.2 to -$189.7, and earnings per share declined from -$0.0013 to -$0.0014.
D
Sell
11/9/2021Upgraded
Vaxil Bio Ltd. (VXLLF) was upgraded to D from E+ on 11/09/2021.
Vaxil Bio Ltd. (VXLLF) was upgraded to D from E+ on 11/09/2021.
E
Sell
11/8/2021Downgrade
Vaxil Bio Ltd. (VXLLF) was downgraded to E+ from D on 11/8/2021 due to a decline in the valuation index, total return index and volatility index.
Vaxil Bio Ltd. (VXLLF) was downgraded to E+ from D on 11/8/2021 due to a decline in the valuation index, total return index and volatility index.
D
Sell
5/1/2020Downgrade
Vaxil Bio Ltd. (VXLLF) was downgraded to D from D+ on 5/1/2020 due to a large decline in the efficiency index and total return index.
Vaxil Bio Ltd. (VXLLF) was downgraded to D from D+ on 5/1/2020 due to a large decline in the efficiency index and total return index.
D
Sell
4/30/2020Downgrade
Vaxil Bio Ltd. (VXLLF) was downgraded to D+ from C- on 4/30/2020 due to a significant decline in the efficiency index, solvency index and growth index. Total capital declined 340.4% from -$89.1 to -$392.4, net income declined 137.69% from -$156.8 to -$372.7, and EBIT declined 133.35% from -$156.8 to -$365.9.
Vaxil Bio Ltd. (VXLLF) was downgraded to D+ from C- on 4/30/2020 due to a significant decline in the efficiency index, solvency index and growth index. Total capital declined 340.4% from -$89.1 to -$392.4, net income declined 137.69% from -$156.8 to -$372.7, and EBIT declined 133.35% from -$156.8 to -$365.9.
C
Hold
2/27/2020Upgraded
Vaxil Bio Ltd. (VXLLF) was upgraded to C- from D+ on 2/27/2020 due to a noticeable increase in the total return index and volatility index.
Vaxil Bio Ltd. (VXLLF) was upgraded to C- from D+ on 2/27/2020 due to a noticeable increase in the total return index and volatility index.
D
Sell
11/29/2019Upgraded
Vaxil Bio Ltd. (VXLLF) was upgraded to D+ from D on 11/29/2019 due to a significant increase in the efficiency index, valuation index and total return index.
Vaxil Bio Ltd. (VXLLF) was upgraded to D+ from D on 11/29/2019 due to a significant increase in the efficiency index, valuation index and total return index.
D
Sell
8/28/2019Upgraded
Vaxil Bio Ltd. (VXLLF) was upgraded to D from E+ on 08/28/2019.
Vaxil Bio Ltd. (VXLLF) was upgraded to D from E+ on 08/28/2019.
E
Sell
5/24/2019Downgrade
Vaxil Bio Ltd. (VXLLF) was downgraded to E+ from D- on 5/24/2019 due to a decline in the efficiency index, solvency index and total return index. Total capital declined 52.55% from $354.7 to $168.3, and the quick ratio declined from 1.78 to 1.41.
Vaxil Bio Ltd. (VXLLF) was downgraded to E+ from D- on 5/24/2019 due to a decline in the efficiency index, solvency index and total return index. Total capital declined 52.55% from $354.7 to $168.3, and the quick ratio declined from 1.78 to 1.41.
D
Sell
4/24/2019Downgrade
Vaxil Bio Ltd. (VXLLF) was downgraded to D- from D on 4/24/2019 due to a major decline in the growth index, solvency index and valuation index. Earnings per share declined from -$0.002 to -$0.0035, EBIT declined 72.74% from -$170.6 to -$294.7, and the quick ratio declined from 3.11 to 1.82.
Vaxil Bio Ltd. (VXLLF) was downgraded to D- from D on 4/24/2019 due to a major decline in the growth index, solvency index and valuation index. Earnings per share declined from -$0.002 to -$0.0035, EBIT declined 72.74% from -$170.6 to -$294.7, and the quick ratio declined from 3.11 to 1.82.
D
Sell
4/8/2019Upgraded
Vaxil Bio Ltd. (VXLLF) was upgraded to D from D- on 4/8/2019 due to an increase in the total return index and volatility index.
Vaxil Bio Ltd. (VXLLF) was upgraded to D from D- on 4/8/2019 due to an increase in the total return index and volatility index.
D
Sell
1/7/2019Downgrade
Vaxil Bio Ltd. (VXLLF) was downgraded to D- from D on 1/7/2019 due to a decline in the total return index, volatility index and valuation index.
Vaxil Bio Ltd. (VXLLF) was downgraded to D- from D on 1/7/2019 due to a decline in the total return index, volatility index and valuation index.
D
Sell
11/30/2018Upgraded
Vaxil Bio Ltd. (VXLLF) was upgraded to D from E+ on 11/30/2018 due to an increase in the valuation index and solvency index. The quick ratio increased from 2.54 to 3.11.
Vaxil Bio Ltd. (VXLLF) was upgraded to D from E+ on 11/30/2018 due to an increase in the valuation index and solvency index. The quick ratio increased from 2.54 to 3.11.
E
Sell
8/30/2018Downgrade
Vaxil Bio Ltd. (VXLLF) was downgraded to E+ from D- on 8/30/2018 due to a noticeable decline in the total return index, volatility index and efficiency index. Total capital declined 16.22% from $756.9 to $634.1.
Vaxil Bio Ltd. (VXLLF) was downgraded to E+ from D- on 8/30/2018 due to a noticeable decline in the total return index, volatility index and efficiency index. Total capital declined 16.22% from $756.9 to $634.1.
D
Sell
6/5/2018Downgrade
Vaxil Bio Ltd. (VXLLF) was downgraded to D- from D on 6/5/2018 due to a decline in the efficiency index.
Vaxil Bio Ltd. (VXLLF) was downgraded to D- from D on 6/5/2018 due to a decline in the efficiency index.
D
Sell
3/12/2018Upgraded
Vaxil Bio Ltd. (VXLLF) was upgraded to D from D- on 3/12/2018 due to a noticeable increase in the total return index and volatility index.
Vaxil Bio Ltd. (VXLLF) was upgraded to D from D- on 3/12/2018 due to a noticeable increase in the total return index and volatility index.
D
Sell
10/3/2017Downgrade
Vaxil Bio Ltd. (VXLLF) was downgraded to D- from D on 10/3/2017 due to a decline in the total return index, volatility index and growth index.
Vaxil Bio Ltd. (VXLLF) was downgraded to D- from D on 10/3/2017 due to a decline in the total return index, volatility index and growth index.
D
Sell
8/31/2017Upgraded
Vaxil Bio Ltd. (VXLLF) was upgraded to D from D- on 8/31/2017 due to an increase in the growth index. Earnings per share increased from -$0.0092 to -$0.0047, EBIT increased 48.17% from -$456.3 to -$236.5, and operating cash flow increased 1.87% from -$219.8 to -$215.7.
Vaxil Bio Ltd. (VXLLF) was upgraded to D from D- on 8/31/2017 due to an increase in the growth index. Earnings per share increased from -$0.0092 to -$0.0047, EBIT increased 48.17% from -$456.3 to -$236.5, and operating cash flow increased 1.87% from -$219.8 to -$215.7.
D
Sell
8/14/2017Downgrade
Vaxil Bio Ltd. (VXLLF) was downgraded to D- from D on 8/14/2017 due to a decline in the volatility index and total return index.
Vaxil Bio Ltd. (VXLLF) was downgraded to D- from D on 8/14/2017 due to a decline in the volatility index and total return index.
D
Sell
7/19/2017Upgraded
Vaxil Bio Ltd. (VXLLF) was upgraded to D from D- on 7/19/2017 due to an increase in the volatility index and total return index.
Vaxil Bio Ltd. (VXLLF) was upgraded to D from D- on 7/19/2017 due to an increase in the volatility index and total return index.
D
Sell
6/30/2017Downgrade
Vaxil Bio Ltd. (VXLLF) was downgraded to D- from D on 6/30/2017 due to a decline in the volatility index.
Vaxil Bio Ltd. (VXLLF) was downgraded to D- from D on 6/30/2017 due to a decline in the volatility index.
D
Sell
6/15/2017Upgraded
Vaxil Bio Ltd. (VXLLF) was upgraded to D from D- on 6/15/2017 due to an increase in the total return index and volatility index.
Vaxil Bio Ltd. (VXLLF) was upgraded to D from D- on 6/15/2017 due to an increase in the total return index and volatility index.
D
Sell
6/5/2017Upgraded
Vaxil Bio Ltd. (VXLLF) was upgraded to D- from E+ on 6/5/2017 due to a large increase in the growth index, efficiency index and total return index. Earnings per share increased from -$0.0102 to -$0.0092, and net income increased 3.83% from -$475.2 to -$457.
Vaxil Bio Ltd. (VXLLF) was upgraded to D- from E+ on 6/5/2017 due to a large increase in the growth index, efficiency index and total return index. Earnings per share increased from -$0.0102 to -$0.0092, and net income increased 3.83% from -$475.2 to -$457.
E
Sell
5/19/2017Downgrade
Vaxil Bio Ltd. (VXLLF) was downgraded to E+ from D- on 5/19/2017 due to a major decline in the growth index, valuation index and solvency index. EBIT declined 114.53% from -$224.3 to -$481.2, earnings per share declined from -$0.0048 to -$0.0102, and the quick ratio declined from 10.09 to 2.21.
Vaxil Bio Ltd. (VXLLF) was downgraded to E+ from D- on 5/19/2017 due to a major decline in the growth index, valuation index and solvency index. EBIT declined 114.53% from -$224.3 to -$481.2, earnings per share declined from -$0.0048 to -$0.0102, and the quick ratio declined from 10.09 to 2.21.
D
Sell
12/1/2016Upgraded
Vaxil Bio Ltd. (VXLLF) was upgraded to D- from E on 12/01/2016.
Vaxil Bio Ltd. (VXLLF) was upgraded to D- from E on 12/01/2016.
E
Sell
9/30/2016None
Vaxil Bio Ltd. (VXLLF) was downgraded to E from U on 09/30/2016.
Vaxil Bio Ltd. (VXLLF) was downgraded to E from U on 09/30/2016.
OTC PK
05/23/2024 11:22AM Eastern
Quotes delayed
